Vaccine Being Tested To Prevent Dementia In People With Down Syndrome

BOSTON (CBS) – Local researchers are testing an experimental vaccine that may not only prevent Alzheimer’s disease in people with Down syndrome, but in those without Down syndrome as well. People with Down syndrome are at high risk of developing Alzheimer’s-like dementia at a very young age. Michael Clayburgh, 29, has Down syndrome, but that doesn’t hold him back. “Michael has three jobs,” says Nancy Novelline Clayburgh, Michael’s mom.  “He works at Target, McDonald’s and Dunkin Donuts.” Dr. Brian Skotko and Michael Clayburgh (WBZ-TV) He’s also quite the Special Olympics athlete, but perhaps Michael’s greatest contribution will be a scientific one. “He could be a major factor in finding the cure to Alzheimer’s,” explains Nancy. People with Down syndrome have an extra copy of chromosome 21.  One of the genes on that chromosome can lead to plaque build-up in the brain. “That goop in the brain when it starts to come together can really disrupt neuronal function and lead to the dementia that’s associated with Alzheimer’s,” explains Dr. Brian Skotko, director of the Down Syndrome Program at Massachusetts General Hospital. He says up to 50 percent of people with Down syndrome will develop dementia by age 50.  He worries about his 38-year-old sister, Kristin, who also has Down syndrome. Dr. Brian Skotko and his sister Kristin (WBZ-TV) “Because o...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Boston News Health Healthwatch Seen On WBZ-TV Syndicated Local Alzheimer's Disease Dementia Down Syndrome Dr. Mallika Marshall Source Type: news

Related Links:

DiscussionThese findings demonstrate that chronic InRapa administration is able to exert a neuroprotective effect on Ts65Dn hippocampus by reducing AD pathological hallmarks and by restoring protein homeostasis, thus ultimately resulting in improved cognition. Results are discussed in term of a potential novel targeted therapeutic approach to reduce cognitive decline and AD-like neuropathology in DS individuals.
Source: Translational Neurodegeneration - Category: Neurology Source Type: research
CONCLUSION: The CAMDEX-DS can be considered the first valid and reliable instrument for evaluating dementia in adults with DS in Brazil. Its use in such individuals could improve clinical practice and research. PMID: 30365671 [PubMed - as supplied by publisher]
Source: Revista Brasileira de Psiquiatria - Category: Psychiatry Authors: Tags: Rev Bras Psiquiatr Source Type: research
ConclusionsThe early white matter damage visible in our DS subjects could have great impact in the therapeutic management, in particular in better adapting the timing of therapies to counteract the toxic effect of the deposition of amyloid that leads to oxidative stress.
Source: Neuroradiology - Category: Radiology Source Type: research
Publication date: Available online 29 August 2018Source: The Lancet NeurologyAuthor(s): Juan Fortea, María Carmona-Iragui, Bessy Benejam, Susana Fernández, Laura Videla, Isabel Barroeta, Daniel Alcolea, Jordi Pegueroles, Laia Muñoz, Olivia Belbin, Mony J de Leon, Aleksandra Maleska Maceski, Christophe Hirtz, Jordi Clarimón, Sebastián Videla, Constance Delaby, Sylvain Lehmann, Rafael Blesa, Alberto LleóSummaryBackgroundDiagnosis of Alzheimer's disease in Down syndrome is challenging because of the absence of validated diagnostic biomarkers. We investigated the diagnostic performance...
Source: The Lancet Neurology - Category: Neurology Source Type: research
We described a 52-year-old female with Down syndrome who developed progressively more frequent myoclonus following cognitive decline and died at the age of 59 years.
Source: Brain and Development - Category: Neurology Authors: Tags: Case Report Source Type: research
ConclusionDisorders associated with early-life alterations in amyloid precursor protein production or processing are associated with a distinct pattern of early striatal fibrillary Aβ deposition before significant cognitive impairment. A better understanding of this unique pattern could identify important mechanisms of Aβ deposition and possibly important targets for early intervention.
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - Category: Geriatrics Source Type: research
PHILADELPHIA - A study on amyloid plaque accumulation, white-matter hyperintensity,...Read more on AuntMinnie.comRelated Reading: Are amyloid PET scans ready for the clinical setting? PET links amyloid, vascular factors to cognitive decline PiB-PET study strengthens link between amyloid, dementia High amyloid levels on PET may indicate early Alzheimer's SNMMI: PiB-PET finds unique Down syndrome trait
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
AbstractDown syndrome, caused by trisomy of chromosome 21, is the single most common risk factor for early-onset Alzheimer ’s disease. Worldwide approximately 6 million people have Down syndrome, and all these individuals will develop the hallmark amyloid plaques and neurofibrillary tangles of Alzheimer’s disease by the age of 40 and the vast majority will go on to develop dementia. Triplication ofAPP, a gene on chromosome 21, is sufficient to cause early-onset Alzheimer ’s disease in the absence of Down syndrome. However, whether triplication of other chromosome 21 genes influences disease pathogenesis i...
Source: Brain - Category: Neurology Source Type: research
The presence of amyloid on PET scans may be a sign that adults with no symptoms...Read more on AuntMinnie.comRelated Reading: High amyloid levels on PET may indicate early Alzheimer's PiB-PET could open window on common meningiomas SNMMI: PET shows tau may be Alzheimer's catalyst SNMMI: PiB-PET finds unique Down syndrome trait PiB-PET shows link between arterial stiffness and beta amyloid
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Authors: Eady N, Sheehan R, Rantell K, Sinai A, Bernal J, Bohnen I, Bonell S, Courtenay K, Dodd K, Gazizova D, Hassiotis A, Hillier R, McBrien J, Mukherji K, Naeem A, Perez-Achiaga N, Sharma V, Thomas D, Walker Z, McCarthy J, Strydom A Abstract BACKGROUND: There is little evidence to guide pharmacological treatment in adults with Down syndrome and Alzheimer's disease. Aims To investigate the effect of cholinesterase inhibitors or memantine on survival and function in adults with Down syndrome and Alzheimer's disease. METHOD: This was a naturalistic longitudinal follow-up of a clinical cohort of 310 people with ...
Source: The British Journal of Psychiatry for Mental Science - Category: Psychiatry Tags: Br J Psychiatry Source Type: research
More News: Alzheimer's | Brain | Clinical Trials | Dementia | Down's Syndrome | Genetics | Health | Hospitals | Jobs | Neurology | Neuroscience | Sports Medicine | Study | Vaccines